NIKKEI 225
38,556.87 -298.50 (-0.77%) HANG SENG
18,477.01 -344.15 (-1.83%) CRUDE OIL
79.02 -0.81 (-1.01%) GOLD FUTURES
2,336.20 -20.30 (-0.86%) DOW
38,441.54 -411.32 (-1.06%) Bitcoin GBP
52,872.20 -966.18 (-1.79%)
NVO Sep 2024 115.000 put
- Yahoo Finance Video
Nvidia, advances in cancer research, climate change under Trump: Market Domination
Nvidia (NVDA) continues to dominate the tech sector as the company's shares move past $1,100. The chip giant earned a boost from Elon Musk, who announced that xAI's supercomputer will run on Nvidia technology. Meanwhile, Tesla (TSLA) shareholders are awaiting an important vote on June 13, which will dictate the fate of Musk's proposed pay package of $56 billion. The American Society of Clinical Oncology (ASCO) will hold its annual meeting in Chicago this week, exploring the latest advancements in the cancer research sector. Tom Steyer, Galvanize Climate Solutions Co-Executive Chair, also joins the show to give insight into the state of climate change mitigation under a possible second Trump presidency. For more expert insight and the latest market action, click here.
- The Telegraph
SSE-backed wind farm fined record £33m for pushing up household bills
A wind farm owned by energy giant SSE is to pay a record fine to the energy regulator after overcharging customers.
- Benzinga
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Novo Nordisk A/S (NYSE:NVO) has disclosed that it retains approximately 60% of the list price of its diabetes and obesity medications, Ozempic and Wegovy, in the U.S. after accounting for rebates and fees paid to intermediaries. This revelation comes amid intensifying scrutiny over the cost of these blockbuster drugs. In a recent letter to Senator Bernie Sanders, the European drug maker expressed willingness to collaborate with lawmakers to tackle systemic issues hindering patients’ access to me
